JURNISTA TABLET (EXTENDED-RELEASE)

País: Canadá

Língua: inglês

Origem: Health Canada

Ingredientes ativos:

HYDROMORPHONE HYDROCHLORIDE

Disponível em:

JANSSEN INC

Código ATC:

N02AA03

DCI (Denominação Comum Internacional):

HYDROMORPHONE

Dosagem:

4MG

Forma farmacêutica:

TABLET (EXTENDED-RELEASE)

Composição:

HYDROMORPHONE HYDROCHLORIDE 4MG

Via de administração:

ORAL

Unidades em pacote:

7/10/30

Tipo de prescrição:

Narcotic (CDSA I)

Área terapêutica:

OPIATE AGONISTS

Resumo do produto:

Active ingredient group (AIG) number: 0108698006; AHFS:

Status de autorização:

CANCELLED POST MARKET

Data de autorização:

2018-10-31

Características técnicas

_232334 APM.doc_
_ _
_Page 1 of 52 _
PRODUCT MONOGRAPH
N
JURNISTA
®
HYDROmorphone hydrochloride Prolonged Release Tablets
4, 8, 16, and 32 mg
Opioid Analgesic
Janssen Inc.
19 Green Belt Drive
Toronto, Ontario
M3C 1L9
www.janssen.com/canada
Distribution Site:
Markham, Ontario
L3R 0T5
Date of Preparation:
November 17, 2009
Date of Revision:
December 13, 2019
SUBMISSION CONTROL NO.: 232334
All trademarks used under license.
© 2019 Janssen Inc.
_232334 APM.doc_
_ _
_Page 2 of 52 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
14
DRUG INTERACTIONS
.........................................................................................................
20
DOSAGE AND ADMINISTRATION
.....................................................................................
22
OVERDOSAGE
.......................................................................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 28
STORAGE AND STABILITY
.................................................................................................
31
SPECIAL HANDLING INSTRUCTIONS
..............................................................................
31
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 31
PART II: SCIENTIFIC INFORMATION
.....